Pharma / Biotech

Keytruda Plus Lenvima Approved for Some Endometrial Cancer Pts

The FDA granted accelerated approval to the combination of pembrolizumab (Keytruda, Merck) plus lenvatinib (Lenvima, Eisai) for the treatment of patients who have advanced endometrial carcinoma that is not microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) and who have disease progression after systemic therapy but are not candidates for curative surgery or radiation.

Source link

Related posts

PROFUSE SWEATING (Pilocarpus Jaborandi Leaf) Pellet [Natural Health Supply]


Simultaneous quantitation of glycyrrhetic acid and puerarin in plasma by UFLC-MS/MS, and application in a pharmacokinetics study in healthy and alcoholic liver injury rats.


SECRET CLINICAL STRENGTH FREE SOFT UNSCENTED (Aluminum Zirconium Trichlorohydrex Gly) Cream [The Procter Gamble Manufacturing Company]


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy